DELCATH SYSTEMS, INC.
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Company / filing name
- DELCATH SYSTEMS, INC. [1]
- Headquarters location
- New York City [2]
- Founded
- 1988 [2]
- Legal form
- Delaware corporation [2]
- Official website
- www.delcath.com ↗ [2]
- ISIN (reported securities)
- US24661P8077 [2]
- CIK
- 872912 [1]
- Country in background record
- United States [2]
- Symbols / exchanges
- DCTH (Nasdaq) [1]
Company positioning and business
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine). [3]
Background text: Wikipedia contributors, Delcath Systems. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
Listed securities: DCTH (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [1]
History and key events
Founding / inception date recorded in Wikidata. [2]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [1]
Related entities and concepts
Frequently asked questions
When was DELCATH SYSTEMS, INC. founded?
Founded: 1988. The linked source provides the background record. [2]
Where is the headquarters of DELCATH SYSTEMS, INC.?
Headquarters location: New York City. The linked source provides the background record. [2]
Sources and review dates
- Company identity and profile data ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Delcath Systems (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.